Compare NPK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | GHRS |
|---|---|---|
| Founded | 1905 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.1M | 1.0B |
| IPO Year | 1994 | 2021 |
| Metric | NPK | GHRS |
|---|---|---|
| Price | $132.58 | $13.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | 78.3K | ★ 206.9K |
| Earning Date | 03-13-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $139.09 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $77.63 | $7.98 |
| 52 Week High | $149.86 | $19.51 |
| Indicator | NPK | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 36.35 |
| Support Level | $127.38 | $12.14 |
| Resistance Level | $137.78 | $14.80 |
| Average True Range (ATR) | 5.95 | 0.84 |
| MACD | -0.56 | -0.20 |
| Stochastic Oscillator | 34.95 | 4.92 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.